» Articles » PMID: 38280996

Mechanisms and Functions of SUMOylation in Health and Disease: a Review Focusing on Immune Cells

Overview
Journal J Biomed Sci
Publisher Biomed Central
Specialty Biology
Date 2024 Jan 27
PMID 38280996
Authors
Affiliations
Soon will be listed here.
Abstract

SUMOylation, which is a type of post-translational modification that involves covalent conjugation of small ubiquitin-like modifier (SUMO) proteins to target substrates, regulates various important molecular and cellular processes, including transcription, the cell cycle, cell signaling, and DNA synthesis and repair. Newly synthesized SUMO is immature and cleaved by the SUMO-specific protease family, resulting in exposure of the C-terminal Gly-Gly motif to become the mature form. In the presence of ATP, mature SUMO is conjugated with the activating enzyme E1 through the cysteine residue of E1, followed by transfer to the cysteine residue of E2-conjugating enzyme Ubc9 in humans that recognizes and modifies the lysine residue of a substrate protein. E3 SUMO ligases promote SUMOylation. SUMOylation is a reversible modification and mediated by SUMO-specific proteases. Cumulative studies have indicated that SUMOylation affects the functions of protein substrates in various manners, including cellular localization and protein stability. Gene knockout studies in mice have revealed that several SUMO cycling machinery proteins are crucial for the development and differentiation of various cell lineages, including immune cells. Aberrant SUMOylation has been implicated in several types of diseases, including cancers, cardiovascular diseases, and autoimmune diseases. This review summarizes the biochemistry of SUMO modification and the general biological functions of proteins involved in SUMOylation. In particular, this review focuses on the molecular mechanisms by which SUMOylation regulates the development, maturation, and functions of immune cells, including T, B, dendritic, and myeloid cells. This review also discusses the underlying relevance of disruption of SUMO cycling and site-specific interruption of SUMOylation on target proteins in immune cells in diseases, including cancers and infectious diseases.

Citing Articles

In-silico structural and functional analysis of nonsynonymous single nucleotide polymorphisms in human gene.

Tondar A, Irfan M, Sanchez-Herrero S, Athar H, Haqqi A, Bepari A In Silico Pharmacol. 2025; 13(1):32.

PMID: 40018382 PMC: 11861814. DOI: 10.1007/s40203-025-00319-3.


Diagnostic and Therapeutic Implications of the SUMOylation Pathway in Acute Myeloid Leukemia.

Chatzikalil E, Arvanitakis K, Filippatos F, Diamantopoulos P, Koufakis T, Solomou E Cancers (Basel). 2025; 17(4).

PMID: 40002226 PMC: 11853134. DOI: 10.3390/cancers17040631.


The intersection of epigenetics and immune thrombocytopenia: new insights into disease mechanisms and treatments.

Zhou X, Shan N Mol Biol Rep. 2025; 52(1):257.

PMID: 39982580 DOI: 10.1007/s11033-025-10363-z.


Epitope and Paratope Mapping of a SUMO-Remnant Antibody Using Cross-Linking Mass Spectrometry and Molecular Docking.

Comtois-Marotte S, Bonneil E, Li C, Smith M, Thibault P J Proteome Res. 2025; 24(3):1092-1101.

PMID: 39965925 PMC: 11895775. DOI: 10.1021/acs.jproteome.4c00717.


Conservation of OFD1 Protein Motifs: Implications for Discovery of Novel Interactors and the OFD1 Function.

Jagodzik P, Zietkiewicz E, Bukowy-Bieryllo Z Int J Mol Sci. 2025; 26(3).

PMID: 39940934 PMC: 11818881. DOI: 10.3390/ijms26031167.


References
1.
Desterro J, Rodriguez M, Kemp G, Hay R . Identification of the enzyme required for activation of the small ubiquitin-like protein SUMO-1. J Biol Chem. 1999; 274(15):10618-24. DOI: 10.1074/jbc.274.15.10618. View

2.
Kamitani T, Kito K, Nguyen H, Yeh E . Characterization of a second member of the sentrin family of ubiquitin-like proteins. J Biol Chem. 1998; 273(18):11349-53. DOI: 10.1074/jbc.273.18.11349. View

3.
Nakamura A, Grossman S, Song K, Xega K, Zhang Y, Cvet D . The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation. Blood. 2022; 139(18):2770-2781. PMC: 11022956. DOI: 10.1182/blood.2021014267. View

4.
Brackett C, Blagg B . Current Status of SUMOylation Inhibitors. Curr Med Chem. 2020; 28(20):3892-3912. PMC: 8483067. DOI: 10.2174/0929867327666200810135039. View

5.
Nishida T, Kaneko F, Kitagawa M, Yasuda H . Characterization of a novel mammalian SUMO-1/Smt3-specific isopeptidase, a homologue of rat axam, which is an axin-binding protein promoting beta-catenin degradation. J Biol Chem. 2001; 276(42):39060-6. DOI: 10.1074/jbc.M103955200. View